Vaxcyte (NASDAQ:PCVX) CFO Sells $572,800.00 in Stock

Posted by Stanley Muller on Jul 9th, 2026

Vaxcyte, Inc. (NASDAQ:PCVX – Get Free Report) CFO Andrew Guggenhime sold 10,000 shares of the stock in a transaction on Monday, July 6th. The stock was sold at an average price of $57.28, for a total transaction of $572,800.00. Following the completion of the transaction, the chief financial officer directly owned 104,395 shares in the company, valued at $5,979,745.60. The trade was a 8.74% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Andrew Guggenhime also recently made the following trade(s):

On Thursday, June 18th, Andrew Guggenhime sold 10,000 shares of Vaxcyte stock. The stock was sold at an average price of $53.00, for a total transaction of $530,000.00.

Vaxcyte Stock Down 3.2%

PCVX opened at $58.71 on Thursday. The stock has a market cap of $8.48 billion, a PE ratio of -8.53 and a beta of 1.22. Vaxcyte, Inc. has a 52 week low of $29.08 and a 52 week high of $65.00. The business’s fifty day simple moving average is $52.14 and its 200 day simple moving average is $53.80.

Vaxcyte (NASDAQ:PCVX – Get Free Report) last issued its quarterly earnings results on Wednesday, May 6th. The company reported ($2.30) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.74) by ($0.56). During the same period in the previous year, the company earned ($1.04) earnings per share. As a group, equities analysts anticipate that Vaxcyte, Inc. will post -7.91 earnings per share for the current year.

Analyst Upgrades and Downgrades

PCVX has been the subject of a number of recent research reports. Wall Street Zen lowered shares of Vaxcyte from a “sell” rating to a “strong sell” rating in a report on Tuesday, April 28th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Vaxcyte in a research report on Monday. Six research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $86.00.

Check Out Our Latest Report on Vaxcyte

Hedge Funds Weigh In On Vaxcyte

A number of large investors have recently bought and sold shares of PCVX. Janus Henderson Group PLC boosted its stake in shares of Vaxcyte by 23.8% during the first quarter. Janus Henderson Group PLC now owns 16,575,875 shares of the company’s stock valued at $960,231,000 after purchasing an additional 3,188,687 shares during the period. T. Rowe Price Investment Management Inc. increased its position in shares of Vaxcyte by 35.9% in the fourth quarter. T. Rowe Price Investment Management Inc. now owns 11,296,333 shares of the company’s stock valued at $521,213,000 after acquiring an additional 2,981,038 shares during the period. Wellington Management Group LLP raised its stake in shares of Vaxcyte by 18.5% during the fourth quarter. Wellington Management Group LLP now owns 5,966,310 shares of the company’s stock valued at $275,286,000 after acquiring an additional 933,539 shares during the last quarter. State Street Corp boosted its holdings in shares of Vaxcyte by 4.1% during the fourth quarter. State Street Corp now owns 4,980,005 shares of the company’s stock worth $229,777,000 after purchasing an additional 194,116 shares during the period. Finally, Paradigm Biocapital Advisors LP boosted its holdings in shares of Vaxcyte by 7.5% during the fourth quarter. Paradigm Biocapital Advisors LP now owns 4,068,020 shares of the company’s stock worth $187,698,000 after purchasing an additional 283,265 shares during the period. 96.78% of the stock is owned by hedge funds and other institutional investors.

Vaxcyte Company Profile

(Get Free Report)

Vaxcyte, Inc (NASDAQ: PCVX) is a clinical-stage biotechnology company focused on developing a new generation of preventive vaccines aimed at combating serious bacterial diseases. Headquartered in San Carlos, California, Vaxcyte leverages proprietary conjugation technologies to design and manufacture multivalent vaccines targeting pathogens for which there remain significant unmet medical needs. The company’s platform is intended to streamline the production of conjugate vaccines by improving antigen presentation and broadening strain coverage compared with conventional approaches.

Vaxcyte’s lead candidate, VAX-24, is a 24-valent pneumococcal conjugate vaccine designed to protect against 24 serotypes of Streptococcus pneumoniae.